Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus bevacizumab in chemotherapy-resistant MSI-like colorectal cancer
2016-002001-19Phase 2Completed
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab, bevacizumab in colorectal cancer (CRC), sponsored by Vall d'Hebron Institute of Oncology. Started Jun 2017; status: completed.
02
Drugs
atezolizumabbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2016-002001-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002001-19.